



REFERENCES

REFERENCES

1. Jain KK. An Overview of Drug Delivery Systems. *Methods Mol Biol.* 2020; 2059:1-54.
2. Penos G. *Index Plantarum Medicinalium Totius Mundi Eorumque Synonymorum* (Ed.). O. E. M.F. Milan; 1983.
3. Farnsworth NR, Akerlee AS, Bingel, Guo ZG and DD. Soejarto. Medicinal Plants in Therapy. *Bull World Health Organ.* 1985; 63(6): 965-981.
4. Vaidya ADB and Devasagayam TPA. Current status of Herbal Drugs in India: An Overview. *J. Clin. Biochem. Nutr.* 2007; 41: 1-11. Vaidya, A.D.B. and T.P.A. Devasagayam. Current status of Herbal Drugs in India: An Overview. *J. Clin. Biochem. Nutr.* 2007; 41: 1-11.
5. Scragg A. Plant cell bioreactors. In: *Plant Cell and Tissue culture* (Eds.). Stafford A. and FG. Warren. Open University Press, Milton Keynes, London; 1991.
6. Hussein A. Status Report on Medicinal Plants for NAM Countries. CSTDNADC, New Delhi; 1993.
7. Patwardhan B, Vaidya ADB and Chorghade M. Ayurveda and natural products drug discovery. *Curr. Sci.* 2004; 86: 789–799.
8. Williams, JC Jr., Mc Ateer, J. A., 2013. Retention and growth of urinary stones: insights from imaging. *J. Nephrol.* 26, 25-31.
9. Tchey, D.U., Ha, Y.S., Kim, W.T., Yun, S.J., Lee, S.C., Kim W.J., 2011. Expect and management of ureter stones: outcome and clinical factors of spontaneous passage in a single institution's experience. *Korean J. Urol.* 52, 847-851.
10. Zhang, D.; Li, S.; Zhang, Z.; Li, N.; Yuan, X.; Jia, Z.; Yang, J. Urinary stone composition analysis and clinical characterization of 1520 patients in central China. *Sci. Rep.* 2021, 11, 6467.
11. Singh, P.; Enders, F.T.; Vaughan, L.E.; Bergstralh, E.J.; Knoedler, J.J.; Krambeck, A.E.; Lieske, J.C.; Rule, A.D. Stone Composition Among First- Time Symptomatic Kidney Stone Formers in the Community. *Mayo Clin. Proc.* 2015, 90, 1356–1365.

12. Siener, R.; Herwig, H.; Rüdiger, J.; Schaefer, R.M.; Lossin, P.; Hesse, A. Urinary stone composition in Germany: Results from 45,783 stone analyses. *World J. Urol.* 2022, 40, 1813–1820.
13. Sakhaee, K.; Adams-Huet, B.; Moe, O.W.; Pak, C.Y. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. *Kidney Int.* 2002, 62, 971–979.
14. Xu, L.H.R.; Adams-Huet, B.; Poindexter, J.R.; Maalouf, N.M.; Moe, O.W.; Sakhaee, K. Temporal Changes in Kidney Stone Composition and in Risk Factors Predisposing to Stone Formation. *J. Urol.* 2017, 197, 1465–1471.
15. Grant, C.M.; Guzman, G.; Stainback, R.P.; Amdur, R.L.; Mufarrij, P.W.; Guzman, G. Variation in Kidney Stone Composition within the United States. *J. Endourol.* 2018, 32, 973–977.
16. Sridevi, V., Rajya Lakshmi, I., Sanjeeva Rao, I., 2004. Urolithiasis (Mutrashmari) In: *Scientific basis for Ayurvedic therapies.*, CRC Press LLC, Florida, pp. 536-548.
17. Li J. W. H, Vederas J. C. Drug discovery and natural products: End of an era or an endless frontier? *Science.* 2009; 325:161–5.
18. Sahoo N, Choudhury K, Manchikanti P. Manufacturing of biodrugs: Need for harmonization in regulatory standards. *BioDrugs.* 2009;23(4):217–29.
19. Micali, S., Grande, M., Sighinolfi, M.C., De Carne, C., De Stefani, S., Bianchi, G., 2006a. Medical therapy of urolithiasis. *J. Endourol.* 20, 841-847
20. Xu, H., Zisman, A.L., Coe, F.L., Worcester, E.M., 2013. Kidney stones: an update on current pharmacological management and future directions. *Expert. Opin. Pharmacother.* 14, 435– 447.
21. López, M., Hoppe, B., 2010. History, epidemiology and regional diversities of urolithiasis. *Pediatr. Nephrol.* 25, 49–59.
22. Mandel, N., 1996. Mechanism of stone formation. *Semin. Nephrol.*, 16, 364- 374.
23. Tiwari, A., Soni, V., Londhe, V., Bhandarkar, A., Bandawane, D., Nipate, S., 2012. An overview on potent indigenous herbs for urinary tract infirmity: urolithiasis. *Asian J. Pharm. Clin. Res.* 5, 7-12.

24. Friedlander, J.I., Antonelli, J.A., Pearle, M.S., 2015. Diet: from food to stone. *World J. Urol.* 33,179-185.
25. Taylor, E.N., Curhan, G.C., 2008. Fructose consumption and the risk of kidney stones. *KidneyInt.*73, 207-212.
26. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. *JAMA.* 2019 Oct 1;322(13):1294-1304.
27. Preminger GM. "Chapter 148: Stones in the Urinary Tract". In Cutler RE (ed.). *The Merck Manual of Medical Information Home Edition (3rd ed.)*. Whitehouse Station, New Jersey: Merck Sharp and Dohme Corporation. Archived from the original. 2014.
28. Nephrolithiasis ~ Overview at eMedicine & Background.
29. Pearle MS, Calhoun EA, Curhan GC (2007). "Ch. 8: Urolithiasis" (PDF). In Litwin MS, Saigal CS (eds.). *Urologic Diseases in America (NIH Publication No. 07–5512)*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services. 2007: 283–319.
30. Cavendish M. "Kidney disorders". *Diseases and Disorders*. Vol. 2 (1st ed.). Tarrytown, New York: Marshall Cavendish Corporation. 2008: 490–3.
31. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ. "Prospective study of beverage use and the risk of kidney stones". *American Journal of Epidemiology.*1996; 143 (3): 240–7.
32. Lewis SM. *Medical-surgical nursing: assessment and management of clinical problems*. 2017.
33. Knight J, Assimosis DG, Easter L, Holmes RP. "Metabolism of fructose to oxalate and glycolate". *Hormone and Metabolic Research.*2010; 42 (12): 868– 73.
34. Moe OW. "Kidney stones: pathophysiology and medical management" (PDF). *Lancet.* 2006; 367 (9507): 333–44.
35. Thakker RV. "Pathogenesis of Dent's disease and related syndromes of X- linked nephrolithiasis" . *Kidney International.* 2000; 57 (3): 787–93.

36. National Endocrine and Metabolic Diseases Information Service . "Hyperparathyroidism (NIH Publication No. 6-3425)". Information about Endocrine and Metabolic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. 2006
37. Hoppe B, Langman CB. "A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria". *Pediatric Nephrology*. 2003;18 (10): 986–
38. Reilly RF, Ch. 13: "Nephrolithiasis". In Reilly & Perazella 2005, pp. 192–207.
39. National Kidney and Urologic Diseases Information Clearinghouse. "Medullary Sponge Kidney (NIH Publication No. 08- 6235)". *Kidney & Urologic Diseases: A-Z list of Topics and Titles*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. 2008.
40. National Digestive Diseases Information Clearinghouse. "Crohn's Disease (NIH Publication No. 06-3410)". *Digestive Diseases: A-Z List of Topics and Titles*. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services. 2006.
41. Farmer RG, Mir-Madjlessi SH, Kiser WS. "Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease". *Cleveland Clinic Quarterly*. 1974; 41 (3): 109-17.
42. Jha V, Garcia-Garcia G, Iseki K, et al. chronic kidney disease: global dimension and perspectives. *Lancet*. 2013;382(9888):260–272.
43. Stamatelou KK, Francis ME, Jones CA. 1976-1994. Time trends in reported prevalence of kidney stones in the United States. *Kidney International*.;63(5):1817-1823.
44. Soucie JM, Thun MJ, Coates RJ. 1994. Demographic and geographic variability of kidney stones in the United States. *Kidney International*, 46(3):893-899

45. Finkelstein VA, Goldfarb DS. Strategies for preventing calcium oxalate stones. *CMAJ* 2006; 174:1407-9.
46. Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE. The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. *J Clin Endocrinol Metab* 1990; 71:861-7.
47. Lemann J Jr, Worcester EM, Gray RW. Hypercalciuria and stones. *Am J Kidney Dis* 1991; 17:386-91.
48. Worcester EM, Coe FL. Nephrolithiasis. *Prim Care* 2008; 35:369-91, vii.
49. Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. *Semin Nephrol* 2008; 28:120-32.
50. Lee YH, Huang WC, Tsai JY. 2002. Epidemiological studies on the prevalence of upper urinary calculi in Taiwan. *Urology – Journal*, 68(3):172 177.
51. Safarinejad MR. 2007. Adult urolithiasis in a population-based study in Iran: prevalence, incidence, and associated risk factors. *Urological Research.*– 35(2):7382.
52. Cameron MA, Sakhaee K. Uric acid nephrolithiasis. *Urol Clin North Am* 2007; 34:335-46.
53. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. *N Engl J Med* 1992; 327:1141-52.
54. Scales CD Jr, Smith AC, Hanley JM. 2012. Prevalence of kidney stones in the United States. *European Urology*, – 62(1):160165.
55. Fattah H, Hambaroush Y, Goldfarb DS. Cystine nephrolithiasis. *Transl Androl Urol* 2014; 3:228-33
56. Trinchieri A, Coppi F, Montanari E. 2000 Increase in the prevalence of symptomatic upper urinary tract stones during the last ten years. *European Urology*, 37(11):23–27.
57. Perazella MA, Ch. 14: "Urinalysis". In Reilly & Perazella 2005, pp. 209–26.
58. Knudsen BE, Beiko DT, Denstedt JD, Ch. 16: "Uric Acid Urolithiasis". In Stoller

- & Meng 2007, pp. 299–308.
59. Nephrolithiasis~Overview at eMedicine § Pathophysiology.
 60. Robertson WG, Peacock M, Nordin BE (July 1969). "Calcium crystalluria in recurrent renal-stone formers". *Lancet*. 2 (7610): 21–24.
 61. Elliot JS, Rabinowitz IN (March 1980). "Calcium oxalate crystalluria: crystal size in urine". *The Journal of Urology*. 123 (3): 324–327.
 62. Randall A (June 1937). "The Origin and Growth of Renal Calculi". *Annals of Surgery*. 105 (6): 1009–1027.
 63. Ratkalkar VN, Kleinman JG (December 2011). "Mechanisms of Stone Formation". *Clinical Reviews in Bone and Mineral Metabolism*. 9 (3–4): 187–197.
 64. Khan SR (September 2014). "Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis". *Translational Andrology and Urology*. 3 (3): 256–276.
 65. Jones BD, Mobley HL (August 1988). "Proteus mirabilis urease: genetic organization, regulation, and expression of structural genes". *Journal of Bacteriology*. 170 (8): 3342–3349.
 66. Chmiel JA, Stuivenberg GA, Alathel A, Gorla J, Grohe B, Razvi H, et al. (December 2021). "High-Throughput in vitro Gel-Based Plate Assay to Screen for Calcium Oxalate Stone Inhibitors". *Urologia Internationalis*. 106 (6): 616– 622.
 67. Kanlaya R, Naruepantawart O, Thongboonkerd V (5 November 2019). "Flagellum Is Responsible for Promoting Effects of Viable Escherichia coli on Calcium Oxalate Crystallization, Crystal Growth, and Crystal Aggregation". *Frontiers in Microbiology*. 10: 2507.
 68. Coe FL, Evan A, Worcester E (October 2005). "Kidney stone disease". *The Journal of Clinical Investigation*. 115 (10): 2598–608.
 69. del Valle EE, Spivacow FR, Negri AL (2013). "[Citrate and renal stones]". *Medicina*. 73 (4): 363–8.
 70. Educate Your Patients about Kidney Stones" (PDF). kidney.org. 2020.
 71. Caudarella R, Vescini F (September 2009). "Urinary citrate and renal stone

- disease: the preventive role of alkali citrate treatment". *Archivio Italiano di Urologia, Andrologia*. 81 (3): 182–7.
72. Anoaia EJ, Paik ML, Resnick MI (2009). "Ch. 7: Anatomic Nephrolithomy". In Graham SD, Keane TE (eds.). *Glenn's Urologic Surgery* (7th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 45–50.
73. Weaver SH, Jenkins P (2002). "Ch. 14: Renal and Urological Care". *Illustrated Manual of Nursing Practice* (3rd ed.). Lippincott Williams & Wilkins.
74. Pietrow PK, Karellas ME (July 2006). "Medical management of common urinary calculi" (PDF). *American Family Physician*. 74 (1): 86–94.
75. Brisbane, Wayne; Bailey, Michael R.; Sorensen, Mathew D. (November 2016). "An overview of kidney stone imaging techniques". *Nature Reviews. Urology*. 13 (11): 654–662.
76. Smith RC, Varanelli M (July 2000). "Diagnosis and management of acute ureterolithiasis: CT is truth". *AJR. American Journal of Roentgenology*. 175 (1): 3–6.
77. Bushinsky D, Coe FL, Moe OW. "Ch. 37: Nephrolithiasis". In Brenner BM (ed.). *Brenner and Rector's The Kidney*. Vol. 1 (8th ed.). Philadelphia: WB Saunders. 2007; 1299–349.
78. Smith RC, Levine J, Rosenfeld AT (September 1999). "Helical CT of urinary tract stones. Epidemiology, origin, pathophysiology, diagnosis, and management". *Radiologic Clinics of North America*. 37 (5): 911–52, v.
79. American College of Emergency Physicians. "Ten Things Physicians and Patients Should Question". *Choosing Wisely*. 2014.
80. "American Urological Association Choosing Wisely". www.choosingwisely.org. Archived from the original on 23 February 2017. Retrieved 28 May 2017.
81. Fang LS. "Chapter 135: Approach to the Patient with Nephrolithiasis". In Goroll AH, Mulley AG (eds.). *Primary care medicine: office evaluation and management of the adult patient* (6th ed.). Philadelphia: Lippincott Williams & Wilkins. 2009; 962–7.

82. Semins MJ, Matlaga BR. "Management of urolithiasis in pregnancy". *International Journal of Women's Health*. 2013; 5: 599–604.
83. Smith-Bindman R, Aubin C, Bailitz J, Bengiamin RN, Camargo CA, Corbo J, et al. "Ultrasonography versus computed tomography for suspected nephrolithiasis". *The New England Journal of Medicine*. 2014; 371 (12): 1100–10.
84. Kravdal, G.; Helgø, D.; Moe, M.K. Kidney stone compositions and frequencies in a Norwegian population. *Scand. J. Urol*. 2019, 53, 139–144.
85. Adomako, E.; Moe, O.W. Uric Acid and Urate in Urolithiasis: The Innocent Bystander, Instigator, and Perpetrator. *Semin. Nephrol*. 2020, 40, 564–573.
86. Khan, S.R.; Pearle, M.S.; Robertson, W.G.; Gambaro, G.; Canales, B.K.; Doizi, S.; Traxer, O.; Tiselius, H.-G. Kidney stones. *Nat. Rev. Dis. Prim*. 2016, 2, 16008.
87. Milliner, D.S.; Murphy, M.E. Urolithiasis in Pediatric Patients. *Mayo Clin. Proc*. 1993, 68, 241–248.
88. Ferrandino, M. Evaluation and Medical Management of Urinary Lithiasis. McDougal, A., Scott, W., Eds. In *Campbell-Walsh urology*, 10th ed.; Elsevier/Saunders: Philadelphia, PA, USA, 2012; pp. 1287–1335.
89. D'Costa, M.R.; Pais, V.M.; Rule, A.D. Leave no stone unturned: Defining recurrence in kidney stone formers. *Curr. Opin. Nephrol. Hypertens*. 2019, 28, 148–153.
90. Uribarri, J.; Oh, M.S.; Carroll, H.J. The First Kidney Stone. *Ann. Intern. Med*. 1989, 111, 1006–1009.
91. Skolarikos, A.; Straub, M.; Knoll, T.; Sarica, K.; Seitz, C.; Petřík, A.; Türk, C. Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: EAU Guidelines. *Eur. Urol*. 2015, 67, 750–763.
92. D'Costa, M.R.; Haley, W.E.; Mara, K.C.; Enders, F.T.; Vrtiska, T.J.; Pais, V.M.; Jacobsen, S.J.; McCollough, C.H.; Lieske, J.C.; Rule, A.D. Symptomatic and Radiographic Manifestations of Kidney Stone Recurrence and Their Prediction by Risk Factors: A Prospective Cohort Study. *J. Am.Soc. Nephrol*. 2019, 30, 1251–1260.
93. Vaughan, L.E.; Enders, F.T.; Lieske, J.C.; Pais, V.M.; Rivera, M.E.; Mehta, R.A.;

- Vrtiska, T.J.; Rule, A.D. Predictors of Symptomatic Kidney Stone Recurrence After the First and Subsequent Episodes. *Mayo Clin. Proc.* 2018, 94, 202–210.
94. Ferraro, P.M.; Curhan, G.C.; D’Addessi, A.; Gambaro, G. Risk of recurrence of idiopathic calcium kidney stones: Analysis of data from the literature. *J. Nephrol.* 2017, 30, 227–233.
95. Wang, K.; Ge, J.; Han, W.; Wang, D.; Zhao, Y.; Shen, Y.; Chen, J.; Chen, D.; Wu, J.; Shen, N.; et al. Risk factors for kidney stone disease recurrence: A comprehensive meta-analysis. *BMC Urol.* 2022, 22, 62.
96. Frassetto, L., I Kohlstadt, I., 2011. Treatment and prevention of kidney stones: an update. *Am. Fam. Physician.* 84,1234-1242.
97. Masarani, M., Dinneen, M., 2007. Ureteric colic: new trends in diagnosis and treatment. *Postgrad. Med. J.* 83,469-472.
98. Evan, A.P., Worcester, E.M., Coe, F.L., Williams, J. Jr., Lingeman, J.E., 2015. Mechanisms of human kidney stone formation. *Urolithiasis*, 43, Suppl 1, 19-32.
99. Abdel-Khalek, M., Sheir, K.Z., Mokhtar, A.A., Eraky, I., Kenawy, M., Bazeed, M., 2004. Prediction of success rate after extra corporeal shock-wave lithotripsy of renal stones—a multivariate analysis model. *Scand. J. Urol. Nephrol.* 38, 161- 167.
100. Yasir, F., Waqar, M.A., 2011. Effect of indigenous plant extracts on calcium oxalate crystallization having a role in urolithiasis. *Urol. Res.* 39,345-350.
101. Tiwari, A., Soni, V., Londhe, V., Bhandarkar, A., Bandawane, D., Nipate, S., 2012. An overview on potent indigenous herbs for urinary tract infirmity: urolithiasis. *Asian J. Pharm. Clin. Res.* 5,7-12.
102. Stamatelou K, Goldfarb DS. Epidemiology of Kidney Stones. In *Healthcare* 2023; 11(3): 424.
103. Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: an update. *American family physician.* 2011 Dec 1;84(11):1234-42.
104. Sridevi, V., Rajya Lakshmi, I., Sanjeeva Rao, I., 2004. Urolithiasis (Mutrashmari) In: *Scientific basis for Ayurvedic therapies.*, CRC Press LLC, Florida, pp. 536-548.

105. Khan M, Jose A, Sharma S. Physiology, Parathyroid Hormone. In: Stat Pearls. Treasure Island (FL): Stat Pearls Publishing; 2023.
106. Jagtap PN, Shriwas S, Patel R. Investigation of Potential Anti-Urolithiatic Activity of Some Herbs By Using Ethylene Glycol Induced Urolithiasis In Animals. *European Journal of Molecular & Clinical Medicine*.2023;10(01).
107. Alomair MK, Alobaid AA, Almajed MA, Alabduladheem LS, Alkhalifah EA, Mohamed ME, Younis NS. Grape Seed Extract and Urolithiasis: Protection Against Oxidative Stress and Inflammation. *Pharmacognosy Magazine*. 2023 Jan 18:09731296221145069.
108. Golla S, Pasala PK, Sura S, Nainita K, Katabathina D. Anti urolithiatic activity of *Cyperusrotundus tubers*: In silico, In vitro and In vivo approaches. *Brazilian Journal of Pharmaceutical Sciences*. 2023 Jan 9;58.
109. Kishor P, PallepatiKavitha SK. Development and Standardization of a Polyherbal Anti Urolithiatic Suspension. *Future J. Pharm. Health. Sci*. 2022; 2(2): 68-83
110. Sharma YK, Gilhotra UK. Effect of Citrus Limon (L.), Citrus AurantiumAnd Citrus Medica On Ethylene Glycol Induced Urolithiasis In Rats. *Journal of Pharmaceutical Negative Results*. 2022 Oct 12:601-8.
111. Kamaraj MC, Ramakrishnan A. Preliminary Phytochemical screening, In vitro antioxidant activity and acute oral toxicity study of polyherbal formulation for chronic kidney disease. *Journal of Drug Delivery and Therapeutics*. 2022 May 15;12(3):43-8.
112. Wanjari MM, Dey YN, Yadav M, Sharma D, Srivastava B, Jamdagni SB, Gaidhani SN, Pawar S. Oral toxicity evaluation of gokshuradiguggulu, an ayurvedic formulation. *Drug and Chemical Toxicology*. 2022 Sep 3;45(5):1986-94.
113. Venkatesan H, Gurusurthy A, Jayaraj R, Venkatachalam L. Antiurolithiatic activity of AavaraiBhavanaiChooranam a Siddha polyherbal formulation on ethylene glycol-induced urolithiasis in Wister albino rats. *Drug Comb Ther*. 2022;4(4):19.
114. Ogoun TR, Ogidi OI, Aye T. Toxicity Studies of Yoyo Cleanser Bitters Poly-

- Herbal Formulation in Albino Rats. World Journal of Pharmaceutical Research. 2022;11(1):1-1.
115. Mishra A, Singh S, Patel R, Shukla R. Effect of Leaves of *Dendrophthoe Elastica* on Kidney Stone and Nephron Protective Activity by Rat. International Journal of Pharmaceutical Research and Applications. 2022; 7(4): 1542-1559
116. Jagtap PN, Vyapari BR, Chavan SS. Evaluation of anti-urolithiatic activity of polyherbal formulation by using in-vivo model. Journal of Advanced Scientific Research. 2021 Apr 30;12(01 Suppl 2):184-94.
117. Khan A, Khan SR. Clinical studies of medicinal plants for their antiurolithic effects: A systematic review. Longhua Chin Med 2022; 5:16
118. Swati Sharma, Dileep Singh Baghel, Amit Mittal, Saurabh Singh, Bimlesh Kumar, Pranav Kumar Prabhakar, Anand Kumar Chaudhary. "Polyherbal Formulation Development and Assessment of its Potential against Urolithiasis (Mutrakricchra) by In-Vitro Technique", Research Journal of Pharmacy and Technology, 2021; 14(4): 1982-1988.
119. Sachin M. Mahajan, Dheeraj T. Baviskar. "Formulation Development and Evaluation of Polyherbal Suspension of Some Medicinal Plants", International Journal of Current Research and Review, 2021; 13(12): 99-106.
120. Chimagave S. S., Jalalpure S. S., Kurangi B. K. "Preparation and development of polyherbal formulation of medicinal plants for antiarthritic activity", Indian J. Health Science Biomed. Res. 2020; 13:120-6.
121. Harikesh Maurya, Tirath Kumar. "Formulation, Standardization, and Evaluation of Polyherbal Dispersible Tablet", International Journal of Applied Pharmaceutics, 2019; 11(1), 158-167.
122. Patel N, Patel J, Patel A, Zala UU. Acute oral toxicity and efficacy of uricare tablet (polyherbal formulation) against bph (benign prostatic hyperplasia). World Journal of Pharmaceutical Research. 2019; 8(10): 1214-1223
123. Baheti D, Kadam S. Antiurolithiatic activity of a polyherbal formulation against calcium oxalate induced urolithiasis in rats. Journal of Advanced Pharmacy Education & Research Jan-Mar. 2013;3(1).

124. Gilhotra UK, Mohan G, Christina AJ. Antilithiatic activity of poly-herbal formulation tablets by in-vitro method. *Journal of Applied Pharmaceutical Science*. 2013 May 30;3(5):043-8.
125. Bodakhe KS, Namdeo KP, Patra KC, Machwal L, Pareta SK. A polyherbal formulation attenuates hyperoxaluria-induced oxidative stress and prevents subsequent deposition of calcium oxalate crystals and renal cell injury in rat kidneys. *Chinese journal of natural medicines*. 2013 Sep 1;11(5):466-71.
126. Deng G, Kurtz RC, Vickers A, et al. "A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients". *J. Ethnopharmacol.* 2011; 136(1):83-87.
127. M. G. Shekar Kumaran, Pralhad S. Patki. "Evaluation of an Ayurvedic formulation (Cystone), in urolithiasis: A double blind, placebo-controlled study." *European Journal of Integrative Medicine*, 2011; 3(1): 23-28.
128. Jain P K, Ravichandran V, Jain PK, Agrawal RK. "High-performance thin layer chromatography method for estimation of andrographolide in herbal extract and polyherbal formulations". *Journal of Saudi Chemical Society*. 2010; 14(4):383-389.
129. Mohammed Haneefa K, Shahima Hanan R, Saraswathi Mohanta, Guru Prasad Nayar, Chandini, "Formulation and evaluation of herbal gel of *Pothosscandens* Linn". *Asian Pac. J. Trop. Med.* 2010; 3(12):988-992.
130. Kuntal Das et al. "Formulation and Evaluation of A Novel Herbal Gel Of Stevia Extract Iranian Journal of Dermatology". 2010; 12(4):117-122.
131. Ajazuddin, Saraf S. "Applications of novel drug delivery system for herbal formulations". *Fitoterapia*. 2010; 81(7):680-689.
132. Shirfule AL, Khobragade CN, Badrinarayan P, Borse YS, Amilkanthwar RH. Phytochemical analysis and antiurolithiatic activity of a polyherbal formulation. *Journal of herbs, spices & medicinal plants*. 2009 Mar 18;15(1):66-72.
133. Sutar NG, Patil VV, Deshmukh TA, Jawle NM, Patil VR, Bhangle SC. "Evaluation of antipyretic activity of seeds of *Moringaoliefera* Lam". *International Journal of Green Pharmacy*. 2009; 10: 148-150.

134. Lakshmi V, Kumar MC, Jameel F, Kodancha G, Udupa AL. "Evaluation of diuretic activity of *Moringaoleifera* (Lam.) pod extract in rats". *Pharmacologyonline*. 2009; 3: 361-365.
135. Jaiswal D, Kumar PR, Mehta S, Watal G. "Effect of *Moringaoleifera* Lam. leaves aqueous extract therapy on hyperglycemic rats". *Journal of Ethnopharmacology*. 2009; 123: 392-396.
136. Hamman JH. "Composition and Applications of Aloe vera Leaf Gel". *Molecules*. 2008; 13(8):1599-1616.
137. P. M. Dandagi, M. B. Patil, V. S. Mastiholimath, A. P. Gadad and R. H. Dhumansure. "Development and Evaluation of Hepatoprotective Polyherbal Formulation Containing Some Indigenous Medicinal Plants", *Indian Journal of Pharmaceutical Sciences*, 2008; 70(2): 265–268.
138. Kaur AD, Ravichandran V, Jain PK, Agrawal RK. "High-performance thin layer chromatography method for estimation of conessine in herbal extract and pharmaceutical dosage formulations". *J. Pharm. Biomed. Anal.* 2008; 46(2):391-394
139. Ram Kumar Roy, Mayank Thakur, V K Dixit, "Development and evaluation of polyherbal formulation for hair growth-promoting activity" *J Cosmet Dermatol*. 2007; 6(2):108-12.
140. Ahemad B, Khan NA, Ahmad G, Inamuddin M. "Analgesic and antipyretic activity of leaf of *Moringaoleifera* Lam". *Hamdurd Medicus*. 2006; 49(3): 9-13.
141. Siddiq A, Anwar F, Manzoor M and Fatima A. "Antioxidant activity of different solvent extracts of *Moringaoleifera* leaves under accelerated storage of sunflower oil". *Asian journal of plants sciences*. 2005; 4(6): 630-635.
142. Siddhuraju P and Becker K. "Antioxidant properties of various solvent extracts of total phenolics constituents from 3 different agro climatic origins of drum stick tree (*Moringaoleifera*) leaves". *J Agric Food Chem*. 2003; 51(8): 2144-2155.
143. L alas S and Tsaknis J. "Extraction and identification of natural antioxidant from the seeds of the *Moringaoleifera* Lam. tree variety of Malawi". *J Am Oil Chemists Soc*. 2002; 79(7): 677-683.

144. Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, and Ray C. Screening of Indian plants for biological activity. *Indian Journal of Experimental Biology*. 1968; 6(1): 232–247.
145. Mishra S, Aeri V, Gaur PK, Jachak SM. Phytochemical, Therapeutic, and Ethnopharmacological Overview for a Traditionally Important Herb: *Boerhaviadiffusa* Linn. Hindawi Publishing Corporation BioMed Research International Volume, 2014.
146. *Boerhavia diffusa* was originally described and published in *Species Plantarum* 1:3. 1753. "*Boerhavia diffusa*". Germplasm Resources Information Network. Agricultural Research Service, United States Department of Agriculture. Retrieved March 14, 2013.
147. Bhowmik Debjit; Kumar K. P. Sampath; Srivastava Shweta; PaswanShravan; SankarAmit; DuttaDutta (2012). "Traditional Indian Herbs: Punarnava and Its Medicinal Importance" (PDF). *Research Journal of Pharmacognosy and Phytochemistry*. 2012;1 (1): 52–57.
148. Sherwin Carlquist. "Dispersal to Islands". *Plant Discoveries: Sherwin Carlquist*. 2008.
149. Ahmed-Belkacem, A; MacAlou, S; Borrelli, F; Capasso, R; Fattorusso, E; Taglialatela-Scafati, O; Di Pietro, A (2007). "Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors". *Journal of Medicinal Chemistry*. 50 (8): 1933–8.
150. "Punarnavine". *Comparative Toxicogenomics Database*. Salisbury Cove, Maine: Mount Desert Island Biological Lab. March 6, 2013. Retrieved March 13, 2013.
151. Mahesh AR, Kumar H, Ranganath MK, Raviraj AD. Detail study on *Boerhaaviadiffusa* plant for its medicinal importance-A Review. *Res J of Pharm Sci* 2012;1(1):28-36.
152. Thakur RS, Puri HS, Husain A. *Major Medicinal Plants of India*. Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow: Uttar Pradesh, India; 1989.p.116.
153. Shrivastava N, Padhya MA. "Punarnavine" profile in the regenerated roots of

- BoerhaaviadiffusaL. from leaf segments. J Current Sci 1995;68:653-56.
154. Meena AK, Niranjana US, Yadav AK, Ajit K, Singh B, Kiran, Rao MM. A Quality Assessment of BoerhaaviaDiffusa Linn. commonly known as 'Punarnava' plant. Int J of Pharmacognosy and Phytochemical Res 2010;2(1):25-8.
155. Santhosha D, Ramesh A, Prasad MS, Kumar DS, Kumar BP, Dhanalakshmi. Punarnava-a review, Res J of Pharm Biological and Chemical Sci 2011;2(4):427-35.
156. R. K. Goel and M. Kaur, "Anti-convulsant activity of boerhaaviadiffusa: plausible role of calcium channel antagonism," Evidence-basedComplementary and Alternative Medicine, 2011.
157. Nadkarni K. M., (1954) Indian Materia Medica., Bombay Popular Prakashan, Mumbai., Vol I, 373.
158. Kirtikar, Basu. Indian medicinal plants, 2nd edition, oriental enterprises, 2003, 2157-2160.
159. Prusti AB, Behera KK. Ethno-medico botanical study of sundargarh district, Orissa, India. Ethnobotanical Leaflets, 2007; 11:148-163.
160. Ramana MV. Ethnomedicinal and ethnoveterinary plants from Boath, Adilabad district, Andhra Pradesh, India. Ethnobotanical Leaflets. 2008; 12:391-400.
161. Hafizur R, Reddy v, Ghosh S, Mistry S. Antioxidant, cytotoxic and hypolipidemic activities of Plumeria alba L. and *Plumeria Rubra* L, American Journal of Life Sciences. 2014, 2:11-15.
162. Dabhadkar D, Zade V, Dawada S, Dhore M, Kodape M. Effect of Alcoholic Pod Extract of *Plumeria Rubra* on Biochemical and Haematological Parameters of Female Albino Rats, Int. J. Pharm. Sci. Rev. 2013; 15:69-74.
163. Ramproshad S, Afroz T, Mondal B, Khan R, Ahmed S. Screening of Phytochemical and Pharmacological activities of leaves of medicinal plant *Plumeria Rubra*, International journal of research in pharmacy and chemistry. 2012; 4:1001-1007.
164. Surendra K, Kumar N, Sharma. Antimicrobial potential of *Plumeria Rubra* syn *Plumeria acutifolia* bark, Der pharma chemical. 2012; 4:1591- 1593.

165. Kalam S, Yegnambatla R, Periasamy G, Kasarla S, Yasmeen N. Antioxidant and Anti-inflammatory Activities of Flowers of *Plumeria Rubra* L. f. rubra and *Plumeria Rubra* f. lutea, A Comparative Study Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2013; 4:743-750.
166. Kumar A, Chand I, Singh AK. Extraction and Evaluation of pharmacological activity of saponin extract of *Plumeria Rubra* leaves, Pharmacology online. 2009; 1:969-974.
167. Cleverston D, de Freitas I, Diego P, de Souza, Eliane S, Araújo. et al. Ramos Antioxidative and proteolytic activities and protein profile of laticifer cells of *Cryptostegiagrandidiflora*, *Plumeriarubra* and *Euphorbia tirucalli* Braz. J. Plant Physiol. 2010; 22:11-22.
168. Gholizadeh A, Kumar M, Balasubrahmanyam A, Sharma S, Narwal S, Lodha ML. Antioxidant activity of antiviral proteins from *Celosia cristata*. J Plant Biochem Biotechnol 2004;13:13-8.
169. Rajendran R. Preliminary phytochemical analysis and anti-bacterial activity of *Mimosa pudica* Linn leaves. JGPT 2009;1:76.
170. Balick JM, Cox PA. Plants, People and Culture: The Science of Ethnobotany. New York: Scientific American Library; 1996. p. 228.
171. Jagtap NS, Khadabadi SS, Ghorpade DS, Banarase NB, Naphade SS. Antimicrobial and antifungal activity of *Centellaasiatica* (L.) Urban. Umbeliferae Res J Pharm Tech 2009;2:328-30.
172. Wijesekera RB. Plant derived medicines and their role in global health. In: The Medicinal Plant Industry. United States: CRC Press; 1991.
173. Chitravadivu C, Bhoopathi M, Balakrishnan V, Elavazhagan T, Jayakumar S. Antimicrobial activity of laehiums prepared by herbal venders, South India. Am Eur J Sci Res 2009;4:142-7.
174. Mohammed R, Das AK, Ariful M, Mollik H, Jahan R, Khan M, et al. An ethnomedicinal survey of Dhamrai Sub-district in Dhaka district, Bangladesh. Am Eur J SustAgric 2009;3:881-8.
175. Kumar Pradeep CB, Mohana KN. Phytochemical screening and corrosion

- inhibitive behavior of *Pterolobiumhexapetalum* and *Celosia argentea* plant extracts on mild steel in industrial water medium. *Egyptian Journal of Petroleum*, 2014; 23(2): 201-211.
176. Linn. *International Journal of Pharma and Bio Sciences*, 2011; 2(3): 463.
177. *Argentea Linn. International Journal of Pharmaceutical and Applied Sciences*, 2010; 1(1): 124-126.
178. Urmila GH, Ganga Rao B, Satyanarayana T. Phytochemical and in-vitro antioxidant activity of methanolic extract of *lactucascariola* and *Celosia argentea* leaves. *Journal of Drug Delivery & Therapeutics*, 2013; 3(4): 114- 117.
179. *Indian Pharmacopoeia* 2014, vol. II,III ;Government of India Ministry of Health & Family Welfare.:959,1864,1865,2050,2143,2766,2821.
180. Raymond C Rowe, *Handbook of Excipients*, Sixth Edition, Royal Pharmaceutical Society of Great Britan, London, UK.
181. Krishnananda P, Ingle Amit, G Deshmukh et.al., *Phytochemicals: Extraction Methods, Identification and Detection of Bioactive Compounds From Plant Extracts Journal Of Pharmacognosy And Phytochemistry* 2017; 6(1): 32-3.
182. Neeraj Tandon, Parul Sharma, *Quality Standards of Indian Medicinal Plants Division, Indian council of medical Research New Delhi,2011. Volume 9, Pg no. 59*
183. Neeraj Tandon, Parul Sharma, *Quality Standards of Indian Medicinal Plants Division, Indian council of medical Research New Delhi, 2017. Volume 15, Pg no. 81.*
184. Khadabadi SS, Deore SL. *Experimental pharmacognosy, a comprehensive guide. Nirali Prakashan. 2013; 2: 1.3-1.4.*
185. Khandelwal K R. *Practical Pharmacognosy –Technique and Experiments. Nirali Prakashan. 2015; 25:1-25.*
186. *The Ayurvedic Pharmacopoeia of India. Part- I, 1st Edition, Vol-II, Government of India, Ministry of Health and Family Welfare Department of Indian system of medicine and homoeopathy. 1989; 142-143.*

187. Quality Control Methods for Medicinal Plant Materials. World Health Organization. Geneva WHO. 1998; 8-30.
188. Harborne JB. Phytochemical Methods: A Guide to Modern Technique of Plant Analysis. Chapman And Hall: London. 2007; 1(37) 69:125-75.
189. H. Wagner, S. 'Black Plant Drug Analysis' A Thin Layer Chromatography Atlas Second Edition, Springer 2007.
190. Balaji LG, Banji D, Banji OJ. (2015). Evaluation of antiurolithiatic activity of the aqueous and alcoholic extracts of roots of boerhaavia diffusa. Indo American Journal of Pharmaceutical Research, 5, 525-530.
191. Chen YQ, Chen HY, Tang QQ, Li YF, Liu XS, Lu FH, Gu YY. Protective effect of quercetin on kidney diseases: From chemistry to herbal medicines. Front Pharmacol. 2022 Sep 2;13:968226. doi: 10.3389/fphar.2022.968226. PMID: 36120321; PMCID: PMC9478191.
192. Pai PG, Chamari Nawarathna S, Kulkarni A, Habeeba, U, Reddy CS., Teerthanath, S., & Shenoy, J. P. (2012). Nephroprotective effect of ursolic Acid in a murine model of gentamicin- induced renal damage. ISRN pharmacology, 2012, 410902.
193. Ding YJ., Sun CY., Wen CC., Chen YH. (2015). Nephroprotective role of resveratrol and ursolic Acid in aristolochic Acid intoxicated zebrafish. Toxins, 7(1), 97–109.
194. Nephroprotective effects of gallic acid and hesperidin in aluminum chloride-induced toxicity in rats, Phytomedicine Plus, Volume 2, Issue 4, 2022, 100378, ISSN 2667-0313
195. Moradi, A., Abolfathi, M., Javadian, M., Heidarian, E., Roshanmehr, H., Khaledi, M., & Nouri, A. (2021). Gallic Acid Exerts Nephroprotective, Anti-Oxidative Stress, and Anti-Inflammatory Effects Against Diclofenac-Induced Renal Injury in Malarats. Archives of medical research, 52(4), 380–388.
196. Albarakati, AJ. A., Baty, R. S., Aljoudi, A. M., Habotta, O. A., Elmahallawy, E. K., Kassab, R. B., & Abdel Moneim, A. E. (2020). Luteolin protects against lead acetate-induced nephrotoxicity through antioxidant, anti-inflammatory, anti-apoptotic, and Nrf2/HO-1 signaling pathways. Molecular biology reports, 47(4),

- 2591–2603.
197. Sadayan, Santhosh & Raghavan Ethanolic extract of *Boerhavia diffusa* attenuates renal fibrosis in chronic kidney disease rats through downregulation of TGF- β Author's name. European Chemical Bulletin. 12. 5089-5117. 10.48047/ecb/2023.12.10.3582023.
198. Malkapuram, Mamatha & Reddy, Suvarchala & Raju, M.. (2021). Antilithiatic activity of leaf extract of citrus medica on sodium oxalate Urolithiasis–in-vitro and in-vivo evaluation. International Journal of Pharmaceutical Sciences and Research. 12. 3709-3715.
199. OECD (2002), Test No. 423: Acute Oral toxicity - Acute Toxic Class Method, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264071001-en>
200. Pareta, Surendra & Patra, K. & Mazumder, P. & Sasmal, Dinakar. (2011). Prophylactic Role of Boerhaavia diffusa in Ethylene Glycol Induced Calcium Oxalate Urolithiasis. African Journal of Urology. 17. 28-36. 10.1007/s12301-011-0007-1.
201. Pareta, Surendra & Patra, Kartik & Mazumder, Papiya & Sasmal, Dinakar. (2010). Boerhaavia diffusa Linn aqueous extract as curative agent in ethylene glycol induced urolithiasis. Pharmacology online. 3.
202. Wexler, B. C. (1963). Histopathology of Kidney Stone Formation in Repeatedly Bred Rats. Journal of Urology, 90(5), 527–534. [https://doi.org/10.1016/S0022-5347\(17\)64450-1](https://doi.org/10.1016/S0022-5347(17)64450-1) (Original work published November 1, 1963)
203. Gunjal AH, Chandola H, Harisha CR, Shukla VJ, Goyal M, Pandya P. Pharmacognostical and Preliminary physicochemical evaluation of Triphaladi granules - A polyherbal Ayurvedic formulation. Ayu. 2013 Jul;34(3):288-93. doi: 10.4103/0974-8520.123128. PMID: 24501525; PMCID: PMC3902596.
204. Sagarika Majhi, Lubhan Singh, Madhu Verma, Iti Chauhan, Raj kumari, Meenakshi Sharma, In-vivo evaluation and formulation development of polyherbal extract in streptozotocin-induced diabetic rat, Phytomedicine Plus, Volume 2, Issue 4, 2022, 100337, ISSN 2667-0313,

<https://doi.org/10.1016/j.phyplu.2022.100337>

205. Kaiyadev Nighantu (Pathyaparhyavibodhak) translated by Sharma P.V. and Sharma G.P., Chaukhbha orientalia 2017, Aushadhivarga, shloka:752-754, pg.139
206. Kaiyadev Nighantu (Pathyaparhyavibodhak) translated by Sharma P.V. and Sharma G.P., Chaukhbha orientalia 2017, Aushadhivarga, shloka:1498-1500, pg.623
207. Kaiyadev Nighantu (Pathyaparhyavibodhak) translated by Sharma P.V. and Sharma G.P., Chaukhbha orientalia 2017, Aushadhivarga, shloka:660-662, pg.122
208. Leon Lachman, Herbert A. Lieberman, Joseph L. Kanig: The hypothesis and Practice of Modern Drug store, Varghese distribution house, 3d release, 1990, 293-373
209. Lohar DR. Protocol for Testing Ayurvedic, Siddha and Unani Medicine, Government of India, Department of AYUSH, Ministry of Health and Family Welfare. Pharmacopoeia Laboratory for Indian Medicines Ghaziabad New Delhi. 11058; 21.